PET/CT with Ga-68-THP-PSMA, a radiotracer developed by King's College London graduate student Jennifer Young, provided increased imaging sensitivity in diagnosing patients with prostate cancer, and the tracer's low cost and easy production process may lead to increased PET/CT access for these patients, researchers reported in the Journal of Nuclear Medicine. Theragnostics CEO Greg Mullen, who was among those who oversaw Young's work, said the company is advancing the tracer's clinical development and "working with regulatory bodies to address an unmet clinical need by bringing this technology to prostate cancer patients."
Novel radiotracer shows promise in assessing prostate cancer
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.